Kausik Chatterjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kausik Chatterjee has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Allam Harfoush
Countess of Chester Hospital NHS Foundation Trust, UK
2 shared publications - Anirban Dutta
University of Texas at El Paso, USA
2 shared publications - Caroline Watkins
Stroke Research Team, School of Nursing and Midwifery, University of Lancashire, Preston, UK
2 shared publications - Sandra Leason
Countess of Chester Hospital NHS Foundation Trust, UK
2 shared publications - A. Hakam Al-Khalidi
Medtronic Limited, Building 9, Croxley Park, Hatters Lane, Watford, WD18 8WW, UK
1 shared publication - Alakendu Sekhar
Department of Neurology, The Walton Centre, Liverpool, L9 7LJ, U.K
1 shared publication
Latest Publications
- Open Access
- 17 November 2026
- Published by MDPI AG in Preprints.org
Systemic Haemodynamic and Neural-Autonomic Coupling During Common Peroneal Nerve Stimulation After Ischaemic Stroke: RETRAIN Phase 1 Study
Objective. Common peroneal nerve neuromuscular electrical stimulation (NMES), given after stroke to prevent venous thromboembolism, was associated with increased fNIRS haemoglobin oxygenation in the published primary analysis. We asked how far these optical responses reflect cardiac, vascular and neural-autonomic physiology, using EEG-fNIRS recordings. Approach. In RETRAIN Phase 1 (16 subacute patients, five NMES intensities), eight operationally distinct physiological families were each represented by one measure. Each was tested for stimulation versus baseline, first-block versus later-block differences and Optimal+1 versus Optimal, with exploratory question-wise Benjamini-Hochberg adjustment. Simulations, two open datasets with short channels and a compartment model set what the measures can mean. Sensitivity analyses excluded participants with a history of atrial fibrillation (AF). Main results. Optically inferred cardiac and respiratory predictors accounted for 29% excess predictability of slow global HbO variance relative to shifted controls. Blocks with larger heart rate rises showed larger global HbO and HbT rises but no HbR change (within-participant z +0.30, p = 0.012). EEG-haemodynamic (+0.034 excess coherence), brain-heart (Granger z +0.64) and cardiac-haemodynamic (+0.19) coupling exceeded surrogate nulls but did not track intensity. Mayer-band HbO power was lower in the first block (nominal), and higher at Optimal+1 than at Optimal (question-wise BH q = 0.002). In the 11 participants without AF, pulse amplitude fell by 12% in the first block (p < 0.001) and rose at Optimal+1 (p = 0.005). Pulse-amplitude contrasts differed by documented AF history (three AF-history participants with usable pulse data, between-group p = 0.003), and optical-pulse usability was 61% versus 93%. Significance. Optical haemodynamic signals co-varied with inferred cardiac and respiratory physiology. EEG-fNIRS coherence indicated cross-modal dependence that shared autonomic modulation and common amplitude envelopes can produce. Pulse-derived outcomes differed by documented AF history. Future studies should verify rhythm by simultaneous ECG and prespecify rhythm-aware analyses.
- 17 November 2026
- Published by MDPI AG in Preprints.org
Open AccessSystemic Haemodynamic and Neural-Autonomic Coupling During Common Peroneal Nerve Stimulation After Ischaemic Stroke: RETRAIN Phase 1 Study
Objective. Common peroneal nerve neuromuscular electrical stimulation (NMES), given after stroke to prevent venous thromboembolism, was associated with increased fNIRS haemoglobin oxygenation in the published primary analysis. We asked how far these optical responses reflect cardiac, vascular and neural-autonomic physiology, using EEG-fNIRS recordings. Approach. In RETRAIN Phase 1 (16 subacute patients, five NMES intensities), eight operationally distinct physiological families were each represented by one measure. Each was tested for stimulation versus baseline, first-block versus later-block differences and Optimal+1 versus Optimal, with exploratory question-wise Benjamini-Hochberg adjustment. Simulations, two open datasets with short channels and a compartment model set what the measures can mean. Sensitivity analyses excluded participants with a history of atrial fibrillation (AF). Main results. Optically inferred cardiac and respiratory predictors accounted for 29% excess predictability of slow global HbO variance relative to shifted controls. Blocks with larger heart rate rises showed larger global HbO and HbT rises but no HbR change (within-participant z +0.30, p = 0.012). EEG-haemodynamic (+0.034 excess coherence), brain-heart (Granger z +0.64) and cardiac-haemodynamic (+0.19) coupling exceeded surrogate nulls but did not track intensity. Mayer-band HbO power was lower in the first block (nominal), and higher at Optimal+1 than at Optimal (question-wise BH q = 0.002). In the 11 participants without AF, pulse amplitude fell by 12% in the first block (p < 0.001) and rose at Optimal+1 (p = 0.005). Pulse-amplitude contrasts differed by documented AF history (three AF-history participants with usable pulse data, between-group p = 0.003), and optical-pulse usability was 61% versus 93%. Significance. Optical haemodynamic signals co-varied with inferred cardiac and respiratory physiology. EEG-fNIRS coherence indicated cross-modal dependence that shared autonomic modulation and common amplitude envelopes can produce. Pulse-derived outcomes differed by documented AF history. Future studies should verify rhythm by simultaneous ECG and prespecify rhythm-aware analyses.
- Open Access
- 30 October 2026
- Published by SAGE Publications in Clinical Rehabilitation
An economic evaluation alongside a randomised controlled trial of Scanning Eye trAining as a Rehabilitation Choice compared to sham training for Hemianopia after stroke (the SEARCH trial)
Objective: To explore the cost-effectiveness of visual scanning training for hemianopia compared to sham training. Design: Randomised controlled trial. Setting: Acute stroke unit and outpatient eye clinics. Participants: Adult stroke survivors with homonymous hemianopia. Intervention: Visual scanning training. Comparator: Sham eye pursuit movements. Main measures: Cost-utility and cost-effectiveness analyses were conducted from UK National Health Service (NHS) and wider societal perspectives. The primary analysis was a cost-utility analysis using EQ-5D-5L utility values. Cost-effectiveness analyses using changes in National Eye Institute-Visual Function Questionnaire-25 item composite and Brain Injury-associated Visual Impairment-Impact Questionnaire scores formed the secondary analyses. Results: Both intervention and sham training packages cost £9.58 (printing costs, clinician time to explain self-administration). Mean total health resource use costs at 26-weeks were higher in the intervention (£1406) than in the sham group (£1339). At 26-weeks, the intervention group gained 0.001 (95%CI:-0.018, 0.021) Quality-Adjusted Life Years (QALY) while the sham group evidenced a QALY loss of −0.002 (95%CI:-0.017, 0.012); not statistically significant (p = 0.71). The Incremental Cost-Effectiveness Ratio of visual scanning training compared to sham was £19,790/QALY, below the National Institute for Health and Care Excellence (NICE) threshold of £20,000–£30,000/QALY. Sensitivity analysis (5000 replications) suggested potential cost-effectiveness of visual scanning training, which had a 67% probability of being cost-effective at £20,000/QALY; this was not significant. Conclusions: This is the first economic evaluation comparing visual scanning training to sham training for treating post-stroke hemianopia. While both interventions had similar costs, the costs were slightly under NICE thresholds. The intervention evidenced marginal but non-significant QALY gain over sham.
- 30 October 2026
- Published by SAGE Publications in Clinical Rehabilitation
Open AccessAn economic evaluation alongside a randomised controlled trial of Scanning Eye trAining as a Rehabilitation Choice compared to sham training for Hemianopia after stroke (the SEARCH trial)
Objective: To explore the cost-effectiveness of visual scanning training for hemianopia compared to sham training. Design: Randomised controlled trial. Setting: Acute stroke unit and outpatient eye clinics. Participants: Adult stroke survivors with homonymous hemianopia. Intervention: Visual scanning training. Comparator: Sham eye pursuit movements. Main measures: Cost-utility and cost-effectiveness analyses were conducted from UK National Health Service (NHS) and wider societal perspectives. The primary analysis was a cost-utility analysis using EQ-5D-5L utility values. Cost-effectiveness analyses using changes in National Eye Institute-Visual Function Questionnaire-25 item composite and Brain Injury-associated Visual Impairment-Impact Questionnaire scores formed the secondary analyses. Results: Both intervention and sham training packages cost £9.58 (printing costs, clinician time to explain self-administration). Mean total health resource use costs at 26-weeks were higher in the intervention (£1406) than in the sham group (£1339). At 26-weeks, the intervention group gained 0.001 (95%CI:-0.018, 0.021) Quality-Adjusted Life Years (QALY) while the sham group evidenced a QALY loss of −0.002 (95%CI:-0.017, 0.012); not statistically significant (p = 0.71). The Incremental Cost-Effectiveness Ratio of visual scanning training compared to sham was £19,790/QALY, below the National Institute for Health and Care Excellence (NICE) threshold of £20,000–£30,000/QALY. Sensitivity analysis (5000 replications) suggested potential cost-effectiveness of visual scanning training, which had a 67% probability of being cost-effective at £20,000/QALY; this was not significant. Conclusions: This is the first economic evaluation comparing visual scanning training to sham training for treating post-stroke hemianopia. While both interventions had similar costs, the costs were slightly under NICE thresholds. The intervention evidenced marginal but non-significant QALY gain over sham.
- Open Access
- 29 July 2026
- Published by Springer Nature in Acta Diabetologica
- p. 1-10
Continuous glucose monitoring and glycaemic variability in acute ischaemic stroke: a systematic review with narrative synthesis
Dysglycaemia is common after acute ischaemic stroke and is associated with adverse outcomes. Continuous glucose monitoring (CGM) provides frequent interstitial glucose measurements and may identify glycaemic variability and excursions missed by intermittent testing. This systematic review evaluated CGM feasibility, accuracy, glycaemic patterns and clinical associations in acute ischaemic stroke. MEDLINE, Embase and CENTRAL were searched to January 2026 for studies of adults undergoing CGM within seven days of stroke onset or admission. Risk of bias was assessed using RoB 2 or the Newcastle–Ottawa Scale, and certainty of evidence using GRADE. Seven studies enrolled 595 participants; monitoring lasted 24 h to 4.5 days. Mean glucose ranged from approximately 118 to 149 mg/dL and coefficient of variation from 4% to 21%. Observational studies provided low- or very-low-certainty evidence that greater hyperglycaemic exposure or variability was associated with death or dependency, unfavourable outcome after thrombectomy and reduced in-hospital neurological improvement. An unadjusted time-above-range difference between functional-trajectory groups was not independently significant after adjustment. One diabetes-only randomised trial evaluated a multi-component intervention combining structured nursing, insulin-pump therapy and CGM. Two-week neurological, motor, self-care and quality-of-life measures favoured the intervention, but modified Rankin Scale and longer-term outcomes were not reported, and the effect of CGM could not be isolated. CGM appears feasible, but evidence is heterogeneous and insufficient to support routine implementation. Standardised metrics and adequately powered multicentre trials are required.
- 29 July 2026
- Published by Springer Nature in Acta Diabetologica
- p. 1-10
Open AccessContinuous glucose monitoring and glycaemic variability in acute ischaemic stroke: a systematic review with narrative synthesis
Dysglycaemia is common after acute ischaemic stroke and is associated with adverse outcomes. Continuous glucose monitoring (CGM) provides frequent interstitial glucose measurements and may identify glycaemic variability and excursions missed by intermittent testing. This systematic review evaluated CGM feasibility, accuracy, glycaemic patterns and clinical associations in acute ischaemic stroke. MEDLINE, Embase and CENTRAL were searched to January 2026 for studies of adults undergoing CGM within seven days of stroke onset or admission. Risk of bias was assessed using RoB 2 or the Newcastle–Ottawa Scale, and certainty of evidence using GRADE. Seven studies enrolled 595 participants; monitoring lasted 24 h to 4.5 days. Mean glucose ranged from approximately 118 to 149 mg/dL and coefficient of variation from 4% to 21%. Observational studies provided low- or very-low-certainty evidence that greater hyperglycaemic exposure or variability was associated with death or dependency, unfavourable outcome after thrombectomy and reduced in-hospital neurological improvement. An unadjusted time-above-range difference between functional-trajectory groups was not independently significant after adjustment. One diabetes-only randomised trial evaluated a multi-component intervention combining structured nursing, insulin-pump therapy and CGM. Two-week neurological, motor, self-care and quality-of-life measures favoured the intervention, but modified Rankin Scale and longer-term outcomes were not reported, and the effect of CGM could not be isolated. CGM appears feasible, but evidence is heterogeneous and insufficient to support routine implementation. Standardised metrics and adequately powered multicentre trials are required.
- 12 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (9) , e214925
Outcomes After Minor Ischemic Stroke in Older Patients Treated With IV Thrombolysis vs Standard of Care in the TEMPO-2 Trial
There are few high-quality data on thrombolysis outcomes in the oldest patients, especially for minor stroke. We examined safety and efficacy outcomes of thrombolysis in patients older than 80 years, compared with those ≤80 years, in the Tenecteplase Versus Standard of care for Minor Ischaemic Stroke With Proven Occlusion (TEMPO-2) trial. In this post hoc analysis of the TEMPO-2 randomized controlled trial, we compared outcomes and adverse events in patients with minor stroke and symptomatic intracranial occlusion or focal perfusion lesion within 12 hours of symptom onset, assigned to tenecteplase vs nonthrombolytic standard of care, in those >80 years and ≤80 years. The primary outcome was responder analysis of the 90-day modified Rankin Scale (responder was mRS = 0-1 if premorbid mRS = 0-1, 0-2 if premorbid mRS = 2). Secondary outcomes included neurologic recovery according to the NIH Stroke Scale (NIHSS) at 5 days/discharge, vessel recanalization, Lawton Instrumental Activities of Daily Living Scale, EuroQol-5 Dimension (EQ-5D), and adverse events. We used mixed-effects Poisson, ordinal logistic, and quantile regression as appropriate, adjusted for sex, baseline NIHSS, and treatment assignment as fixed-effects and enrolling site as random effects. Among 884 patients in the intention-to-treat analysis (208 [23.5%] >80 years, 365 [41.6%] female). Significant interactions between age and treatment were observed for mRS responder, mRS 0-1, return to baseline function, EQ-5D index, and vessel recanalization. Patients >80 years generally fared worse with tenecteplase for mRS outcomes (mRS 0-1 in 49 [46.2%] vs 61 [59.8%] with control, adjusted risk ratio [aRR] 0.83, 95% CI 0.72-0.97), while among patients ≤80 years, there was no significant difference (249 [76.4%] vs 260 [74.7%], aRR 1.01, 95% CI 0.98-1.03). However, in both age groups, patients were more likely to achieve recanalization of visible occlusions (aRR ≤80 years 2.06, 95% CI 1.60-2.65, >80 years 2.77, 95% CI 2.21-3.47) and NIHSS = 0 at 5 days/discharge when assigned to tenecteplase (aRR ≤80 years 1.14, 95% CI 1.04-1.26, >80 years 1.21, 95% CI 1.10-1.33). Serious adverse events (SAEs) were more frequent with tenecteplase among patients >80 years (risk ratio 2.29, 95% CI 1.27-4.13), particularly hemorrhages and stroke progression/recurrence (any extra/intracranial hemorrhage in 5 [4.7%] vs 0 with standard of care, p = 0.026). Older patients (>80 years) with minor stroke and visible occlusion or perfusion lesion assigned to tenecteplase were more likely to achieve recanalization of occlusions and short-term neurologic recovery, as were younger patients, but they experienced worse 90-day outcomes with more frequent hemorrhagic and stroke progression/recurrence-related SAEs. Overall, these results, while post hoc, do not support thrombolysis for minor strokes in older patients. ClinicalTrials.gov: NCT02398656. This study provides Class III evidence that in patients >80 years with minor stroke and visible occlusion or perfusion lesion, IV thrombolysis with tenecteplase is associated with worse functional outcomes at 90 days compared with nonthrombolytic standard of care therapies.
- 12 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (9) , e214925
Outcomes After Minor Ischemic Stroke in Older Patients Treated With IV Thrombolysis vs Standard of Care in the TEMPO-2 Trial
There are few high-quality data on thrombolysis outcomes in the oldest patients, especially for minor stroke. We examined safety and efficacy outcomes of thrombolysis in patients older than 80 years, compared with those ≤80 years, in the Tenecteplase Versus Standard of care for Minor Ischaemic Stroke With Proven Occlusion (TEMPO-2) trial. In this post hoc analysis of the TEMPO-2 randomized controlled trial, we compared outcomes and adverse events in patients with minor stroke and symptomatic intracranial occlusion or focal perfusion lesion within 12 hours of symptom onset, assigned to tenecteplase vs nonthrombolytic standard of care, in those >80 years and ≤80 years. The primary outcome was responder analysis of the 90-day modified Rankin Scale (responder was mRS = 0-1 if premorbid mRS = 0-1, 0-2 if premorbid mRS = 2). Secondary outcomes included neurologic recovery according to the NIH Stroke Scale (NIHSS) at 5 days/discharge, vessel recanalization, Lawton Instrumental Activities of Daily Living Scale, EuroQol-5 Dimension (EQ-5D), and adverse events. We used mixed-effects Poisson, ordinal logistic, and quantile regression as appropriate, adjusted for sex, baseline NIHSS, and treatment assignment as fixed-effects and enrolling site as random effects. Among 884 patients in the intention-to-treat analysis (208 [23.5%] >80 years, 365 [41.6%] female). Significant interactions between age and treatment were observed for mRS responder, mRS 0-1, return to baseline function, EQ-5D index, and vessel recanalization. Patients >80 years generally fared worse with tenecteplase for mRS outcomes (mRS 0-1 in 49 [46.2%] vs 61 [59.8%] with control, adjusted risk ratio [aRR] 0.83, 95% CI 0.72-0.97), while among patients ≤80 years, there was no significant difference (249 [76.4%] vs 260 [74.7%], aRR 1.01, 95% CI 0.98-1.03). However, in both age groups, patients were more likely to achieve recanalization of visible occlusions (aRR ≤80 years 2.06, 95% CI 1.60-2.65, >80 years 2.77, 95% CI 2.21-3.47) and NIHSS = 0 at 5 days/discharge when assigned to tenecteplase (aRR ≤80 years 1.14, 95% CI 1.04-1.26, >80 years 1.21, 95% CI 1.10-1.33). Serious adverse events (SAEs) were more frequent with tenecteplase among patients >80 years (risk ratio 2.29, 95% CI 1.27-4.13), particularly hemorrhages and stroke progression/recurrence (any extra/intracranial hemorrhage in 5 [4.7%] vs 0 with standard of care, p = 0.026). Older patients (>80 years) with minor stroke and visible occlusion or perfusion lesion assigned to tenecteplase were more likely to achieve recanalization of occlusions and short-term neurologic recovery, as were younger patients, but they experienced worse 90-day outcomes with more frequent hemorrhagic and stroke progression/recurrence-related SAEs. Overall, these results, while post hoc, do not support thrombolysis for minor strokes in older patients. ClinicalTrials.gov: NCT02398656. This study provides Class III evidence that in patients >80 years with minor stroke and visible occlusion or perfusion lesion, IV thrombolysis with tenecteplase is associated with worse functional outcomes at 90 days compared with nonthrombolytic standard of care therapies.
- Open Access
- 26 September 2025
- Published by Springer Nature in Journal of Health, Population and Nutrition
- Vol. 44 (1) , 1-11
Assessing stroke survivors’ knowledge: a scoping review of tools and influencing factors
Background: Stroke survivors’ knowledge of their condition is essential for self-management and adherence to secondary prevention strategies. However, current methods for assessing stroke knowledge are not consistent. This scoping review aimed to review existing assessment tools, evaluate their characteristics, and identify factors associated with stroke knowledge to inform the development of more effective, patient-centred educational strategies. Review design and methods: A scoping review was conducted to evaluate existing methods used to assess stroke knowledge and the factors influencing patients’ knowledge among stroke survivors. Systematic searches of PubMed, Cochrane, and CINAHL were performed from inception to June 2025. Studies assessing stroke survivors’ knowledge were included. Data were extracted on tool characteristics, assessed themes, administration methods, readability, validation, and knowledge-associated factors. Findings were qualitatively synthesised. Results: Thirty-nine studies were included. Most studies assessed mixed cohorts of ischaemic, haemorrhagic, and TIAs. Stroke symptoms and risk factors were the most frequently assessed themes, while rehabilitation, medications, and lifestyle behaviours were less explored. Tools were primarily self-administered questionnaires, typically completed in under 15 min, but often lacked standardised cut-off values and demonstrated limited reporting of development processes. Factors positively associated with knowledge included higher education, younger age, and healthier lifestyles. Conclusion: Existing assessments of stroke survivors’ knowledge have considerable variability, limited validation, and inconsistent alignment with survivors’ information needs. Developing standardised, validated, and patient-centred assessment tools that are tailored to stroke type and accessible across literacy levels is essential for advancing stroke education and supporting long-term recovery. These findings can inform policymakers in tailoring education efforts and designing interventions that directly address knowledge gaps across diverse stroke survivor populations. Future research should prioritise longitudinal evaluation of knowledge and its impact on clinical outcomes.
- 26 September 2025
- Published by Springer Nature in Journal of Health, Population and Nutrition
- Vol. 44 (1) , 1-11
Open AccessAssessing stroke survivors’ knowledge: a scoping review of tools and influencing factors
Background: Stroke survivors’ knowledge of their condition is essential for self-management and adherence to secondary prevention strategies. However, current methods for assessing stroke knowledge are not consistent. This scoping review aimed to review existing assessment tools, evaluate their characteristics, and identify factors associated with stroke knowledge to inform the development of more effective, patient-centred educational strategies. Review design and methods: A scoping review was conducted to evaluate existing methods used to assess stroke knowledge and the factors influencing patients’ knowledge among stroke survivors. Systematic searches of PubMed, Cochrane, and CINAHL were performed from inception to June 2025. Studies assessing stroke survivors’ knowledge were included. Data were extracted on tool characteristics, assessed themes, administration methods, readability, validation, and knowledge-associated factors. Findings were qualitatively synthesised. Results: Thirty-nine studies were included. Most studies assessed mixed cohorts of ischaemic, haemorrhagic, and TIAs. Stroke symptoms and risk factors were the most frequently assessed themes, while rehabilitation, medications, and lifestyle behaviours were less explored. Tools were primarily self-administered questionnaires, typically completed in under 15 min, but often lacked standardised cut-off values and demonstrated limited reporting of development processes. Factors positively associated with knowledge included higher education, younger age, and healthier lifestyles. Conclusion: Existing assessments of stroke survivors’ knowledge have considerable variability, limited validation, and inconsistent alignment with survivors’ information needs. Developing standardised, validated, and patient-centred assessment tools that are tailored to stroke type and accessible across literacy levels is essential for advancing stroke education and supporting long-term recovery. These findings can inform policymakers in tailoring education efforts and designing interventions that directly address knowledge gaps across diverse stroke survivor populations. Future research should prioritise longitudinal evaluation of knowledge and its impact on clinical outcomes.
- Open Access
- 17 September 2025
- Published by MDPI AG in Preprints.org
Cerebral Hemodynamics Modulation in Subacute Stroke: Predictors of Responsiveness to Common Peroneal NMES
Background: Enhancing cerebral perfusion after stroke may aid recovery, but individual responsiveness to neuromuscular electrical stimulation (NMES) remains unclear. Objective: To identify predictors of cerebral hemodynamic response to common peroneal NMES in subacute stroke. Methods: In this observational study (RETRAIN Phase 1, NCT06614400), 18 patients underwent functional near-infrared spectroscopy (fNIRS) during NMES at varying postures and intensities. Responders were defined by top-quartile increases in oxygenated hemoglobin (HbO). Predictors were assessed using AUROC screening and LASSO logistic regression with crossvalidation. Results: The final model (AUROC = 0.723) retained 13 predictors, including cortical lesion location (OR = 1.66), atrial fibrillation (OR = 1.28), and ASPECTS thalamic and caudate involvement. Permutation analysis confirmed predictor robustness. Conclusion: This study demonstrates a clinically interpretable machine learning framework to stratify stroke patients by NMES responsiveness. Larger studies with outcome validation are warranted.
- 17 September 2025
- Published by MDPI AG in Preprints.org
Open AccessCerebral Hemodynamics Modulation in Subacute Stroke: Predictors of Responsiveness to Common Peroneal NMES
Background: Enhancing cerebral perfusion after stroke may aid recovery, but individual responsiveness to neuromuscular electrical stimulation (NMES) remains unclear. Objective: To identify predictors of cerebral hemodynamic response to common peroneal NMES in subacute stroke. Methods: In this observational study (RETRAIN Phase 1, NCT06614400), 18 patients underwent functional near-infrared spectroscopy (fNIRS) during NMES at varying postures and intensities. Responders were defined by top-quartile increases in oxygenated hemoglobin (HbO). Predictors were assessed using AUROC screening and LASSO logistic regression with crossvalidation. Results: The final model (AUROC = 0.723) retained 13 predictors, including cortical lesion location (OR = 1.66), atrial fibrillation (OR = 1.28), and ASPECTS thalamic and caudate involvement. Permutation analysis confirmed predictor robustness. Conclusion: This study demonstrates a clinically interpretable machine learning framework to stratify stroke patients by NMES responsiveness. Larger studies with outcome validation are warranted.
- Open Access
- 10 March 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Neural Systems and Rehabilitation Engineering
- Vol. 30 (15344320) , 719-728
Immersive Virtual Reality for the Cognitive Rehabilitation of Stroke Survivors
We present the results of a double-blind phase 2b randomized control trial that used a custom built virtual reality environment for the cognitive rehabilitation of stroke survivors. A stroke causes damage to the brain and problem solving, memory and task sequencing are commonly affected. The brain can recover to some extent, however, and stroke patients have to relearn how to carry out activities of daily living. We have created an application called VIRTUE to enable such activities to be practiced using immersive virtual reality. Gamification techniques enhance the motivation of patients such as by making the level of difficulty of a task increase over time. The design and implementation of VIRTUE is described together with the results of the trial conducted within the Stroke Unit of a large hospital. We report on the safety and acceptability of VIRTUE. We have also observed particular benefits of VR treatment for stroke survivors that experienced more severe cognitive impairment, and an encouraging reduction in time spent in the hospital for all patients that received the VR treatment.
- 10 March 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Neural Systems and Rehabilitation Engineering
- Vol. 30 (15344320) , 719-728
Open AccessImmersive Virtual Reality for the Cognitive Rehabilitation of Stroke Survivors
We present the results of a double-blind phase 2b randomized control trial that used a custom built virtual reality environment for the cognitive rehabilitation of stroke survivors. A stroke causes damage to the brain and problem solving, memory and task sequencing are commonly affected. The brain can recover to some extent, however, and stroke patients have to relearn how to carry out activities of daily living. We have created an application called VIRTUE to enable such activities to be practiced using immersive virtual reality. Gamification techniques enhance the motivation of patients such as by making the level of difficulty of a task increase over time. The design and implementation of VIRTUE is described together with the results of the trial conducted within the Stroke Unit of a large hospital. We report on the safety and acceptability of VIRTUE. We have also observed particular benefits of VR treatment for stroke survivors that experienced more severe cognitive impairment, and an encouraging reduction in time spent in the hospital for all patients that received the VR treatment.
- Open Access
- 17 December 2019
- Published by Springer Nature in Systematic Reviews
- Vol. 8 (1) , 1-5
Etiologic workup in cases of cryptogenic stroke: protocol for a systematic review and comparison of international clinical practice guidelines
Background: Stroke is a leading cause of death and disability worldwide. Identifying the aetiology of ischaemic stroke is essential in order to initiate appropriate and timely secondary prevention measures to reduce the risk of recurrence. For the majority of ischaemic strokes, the aetiology can be readily identified, but in at least 30% of cases, the exact aetiology cannot be determined using existing investigative protocols. Such strokes are classed as ‘cryptogenic’ or as a stroke of unknown origin. However, there exists substantial variation in clinical practice when investigating cases of seemingly cryptogenic stroke, often reflecting local service availability and the preferences of treating clinicians. This variation in practice is compounded by the lack of international consensus as to the optimum level and timing of investigations required following a stroke. To address this gap, we aim to systematically review and compare recommendations in evidence-based clinical practice guidelines (CPGs) that relate to the assessment and investigation of the aetiology of ischaemic stroke, and any subsequent diagnosis of cryptogenic stroke. Method: We will search for CPGs using electronic databases (MEDLINE, Health Management Information Consortium (HMIC), EMBASE, and CINAHL), relevant websites and search engines (e.g. guideline specific websites, governmental, charitable, and professional practice organisations) and hand-searching of bibliographies and reference lists. Two reviewers will independently screen titles, abstracts and CPGs using a pre-defined relevance criteria form. From each included CPG, we will extract definitions and terms for cryptogenic stroke; recommendations related to assessment and investigation of the aetiology of stroke, including the grade of recommendations and underpinning evidence. The quality of the included CPGs will be assessed using the AGREE II (Appraisal of Guidelines for Research and Evaluation) tool. Recommendations across the CPGs will be summarised descriptively highlighting areas of convergence and divergence between CPGs. Discussion: To our knowledge, this will be the first review to systematically compare recommendations of international CPGs on investigating the aetiology of ischaemic stroke. The findings will allow for a better understanding of international perspectives on the optimum level of investigations required following a stroke and thus contribute to achieving greater international consensus on best practice in this important and complex area. Systematic review registration: PROSPERO CRD42019127822.
- 17 December 2019
- Published by Springer Nature in Systematic Reviews
- Vol. 8 (1) , 1-5
Open AccessEtiologic workup in cases of cryptogenic stroke: protocol for a systematic review and comparison of international clinical practice guidelines
Background: Stroke is a leading cause of death and disability worldwide. Identifying the aetiology of ischaemic stroke is essential in order to initiate appropriate and timely secondary prevention measures to reduce the risk of recurrence. For the majority of ischaemic strokes, the aetiology can be readily identified, but in at least 30% of cases, the exact aetiology cannot be determined using existing investigative protocols. Such strokes are classed as ‘cryptogenic’ or as a stroke of unknown origin. However, there exists substantial variation in clinical practice when investigating cases of seemingly cryptogenic stroke, often reflecting local service availability and the preferences of treating clinicians. This variation in practice is compounded by the lack of international consensus as to the optimum level and timing of investigations required following a stroke. To address this gap, we aim to systematically review and compare recommendations in evidence-based clinical practice guidelines (CPGs) that relate to the assessment and investigation of the aetiology of ischaemic stroke, and any subsequent diagnosis of cryptogenic stroke. Method: We will search for CPGs using electronic databases (MEDLINE, Health Management Information Consortium (HMIC), EMBASE, and CINAHL), relevant websites and search engines (e.g. guideline specific websites, governmental, charitable, and professional practice organisations) and hand-searching of bibliographies and reference lists. Two reviewers will independently screen titles, abstracts and CPGs using a pre-defined relevance criteria form. From each included CPG, we will extract definitions and terms for cryptogenic stroke; recommendations related to assessment and investigation of the aetiology of stroke, including the grade of recommendations and underpinning evidence. The quality of the included CPGs will be assessed using the AGREE II (Appraisal of Guidelines for Research and Evaluation) tool. Recommendations across the CPGs will be summarised descriptively highlighting areas of convergence and divergence between CPGs. Discussion: To our knowledge, this will be the first review to systematically compare recommendations of international CPGs on investigating the aetiology of ischaemic stroke. The findings will allow for a better understanding of international perspectives on the optimum level of investigations required following a stroke and thus contribute to achieving greater international consensus on best practice in this important and complex area. Systematic review registration: PROSPERO CRD42019127822.
- Open Access
- 1 July 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-12
PULSE-I - Is rePetitive Upper Limb SEnsory stimulation early after stroke feasible and acceptable? A stratified single-blinded randomised controlled feasibility study
Reduction in sensorimotor function of the upper limb is a common and persistent impairment after stroke, and less than half of stroke survivors recover even basic function of the upper limb after a year. Previous work in stroke has shown that repetitive sensory stimulation (RSS) of the upper limb may benefit motor function. As yet, there have been no investigations of RSS in the early-acute period despite this being the time window during which the neuroplastic processes underpinning sensorimotor recovery are likely to occur. A single-blinded, stratified, randomised controlled feasibility study was undertaken at two NHS acute trusts to determine the recruitment rate, intervention adherence, and safety and acceptability of an RSS intervention in the early period after stroke. Participants were recruited within 2 weeks of index stroke. Stratified on arm function, they were randomised to receive either 45 min of daily RSS and usual care or usual care alone (UC) for 2 weeks. Changes from baseline on the primary outcome of the Action Research Arm Test (ARAT) to measurements taken by a blinded assessor were examined after completion of the intervention (2 weeks) and at 3 months from randomisation. Forty patients were recruited and randomised (RSS n = 23; UC n = 17) with a recruitment rate of 9.5% (40/417) of patients admitted with a stroke of which 52 (12.5%) were potentially eligible, with 10 declining to participate for various reasons. Participants found the RSS intervention acceptable and adherence was good. The intervention was safe and there were no serious adverse events. This study indicates that recruitment to a trial of RSS in the acute period after stroke is feasible. The intervention was well tolerated and appeared to provide additional benefit to usual care. In addition to a definitive trial of efficacy, further work is warranted to examine the effects of varying doses of RSS upon arm function and the mechanism by which RSS induces sensorimotor recovery in the acute period after stroke. ISRCTN, registry no: ISRCTN17422343 ; IRAS Project ID: 215137. Registered on October 2016
- 1 July 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-12
Open AccessPULSE-I - Is rePetitive Upper Limb SEnsory stimulation early after stroke feasible and acceptable? A stratified single-blinded randomised controlled feasibility study
Reduction in sensorimotor function of the upper limb is a common and persistent impairment after stroke, and less than half of stroke survivors recover even basic function of the upper limb after a year. Previous work in stroke has shown that repetitive sensory stimulation (RSS) of the upper limb may benefit motor function. As yet, there have been no investigations of RSS in the early-acute period despite this being the time window during which the neuroplastic processes underpinning sensorimotor recovery are likely to occur. A single-blinded, stratified, randomised controlled feasibility study was undertaken at two NHS acute trusts to determine the recruitment rate, intervention adherence, and safety and acceptability of an RSS intervention in the early period after stroke. Participants were recruited within 2 weeks of index stroke. Stratified on arm function, they were randomised to receive either 45 min of daily RSS and usual care or usual care alone (UC) for 2 weeks. Changes from baseline on the primary outcome of the Action Research Arm Test (ARAT) to measurements taken by a blinded assessor were examined after completion of the intervention (2 weeks) and at 3 months from randomisation. Forty patients were recruited and randomised (RSS n = 23; UC n = 17) with a recruitment rate of 9.5% (40/417) of patients admitted with a stroke of which 52 (12.5%) were potentially eligible, with 10 declining to participate for various reasons. Participants found the RSS intervention acceptable and adherence was good. The intervention was safe and there were no serious adverse events. This study indicates that recruitment to a trial of RSS in the acute period after stroke is feasible. The intervention was well tolerated and appeared to provide additional benefit to usual care. In addition to a definitive trial of efficacy, further work is warranted to examine the effects of varying doses of RSS upon arm function and the mechanism by which RSS induces sensorimotor recovery in the acute period after stroke. ISRCTN, registry no: ISRCTN17422343 ; IRAS Project ID: 215137. Registered on October 2016